Bangalore: Infosys Ltd has designed an innovative cloud-based user portal for the US-based diagnostic-service provider NovaSom to test obstructive sleep apnea (OSA), a medical condition affecting over 40 million Americans, the Indian IT bellwether said Tuesday.
"The portal, MeditrackR on Salesforce.com will provide physicians an easy interface to speed up the order-to-delivery of devices, processing of diagnostic data and management of insurance claims," Infosys global head for life sciences V.G. Dheeshjith said in a statement here Tuesday.
The portal also provides web interfaces with third-party applications to access and analyse patient data received online from the sleep test at home. The software helps NovaSom's sleep customers to deliver faster diagnoses to patients and hasten their treatment.
As the most common syndrome, sleep apnea (without breath) is caused by obstruction of the upper airway during sleep due to reduction in bloody oxygen saturation and lasts about 20-40 seconds.
"As patients with the breathless symptom face risk of other chronic diseases, the solution helps receive faster medical care," Dheeshjith said.
The diagnostic solution also leverages NovaSom's AccuSomR, the first and only FDA-cleared wireless home sleep testing device.
With over 18 million moderate to severe cases of OSA in the US, NovaSom's cost-effective home sleep testing solution is delivering benefits to patients, health insurers, and specialty and primary care physicians.
NovaSom unveiled in 2012 AccuSom solution as a customised turnkey solution to enable specialists to provide at-home sleep testing into their practice on a large-scale.
"The new portal has helped NovaSom scale operations to meet the expanded solution portfolio. Sleep specialists, surgeons and anesthesiologists can develop a patient management plan to minimise the risk of adverse respiratory events and other OSA-related complications during and after surgery," the statement noted.
NovaSom chief executive Richard Hassett said a quicker OSA diagnosis was critical to help sufferers get the therapy they need sooner.
"The portal enables us to complete tests quickly and accurately besides allowing us to partner with providers to improve access to care, reduce cost and address this undiagnosed epidemic," Hassett added.